Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where Things Stand For Vanda Pharmaceuticals In Fanapt Patent Suit http://marketexclusive.com/things-stand-vanda-pharmaceuticals-inc-nasdaqvnda-fanapt-patent-suit/24951/?icd1
* * $VNDA Video Chart 08-25-16 * *
Link to Video - click here to watch the technical chart video
Approved!!!!!
VNDA PDUFA Friday:
The FDA has set a user fee goal date under the Prescription Drug User Fee Act of May 27, 2016, which is the target date for the FDA to complete its review of the sNDA.
Nice been following this stock for awhile now and made some good money here.
Also, follow Titan Pharmaceuticals TTNP
Vanda-Pharmaceuticals Reports Fourth-Quarter 2014 and Full-Year 2014 Financial-Results
Everything comes when you least expect!!!Patience!
Surprising not much interest in this stock it trades all over the place in the last year.
Not many investors. VNDA, have a very high margin requirement(70%)
Why doesnt anyone post info on the Vanda board? is it that good or that bad?
Now I understand the new analyst target $ 6
These are the funds that bought in March 2014
FMR 4.52M $73.37M March 31, 2014
Baker Bros. Advisors 4.45M $72.24M March 31, 2014
Palo Alto Investors 3.22M $52.25M March 31, 2014
Kingdon Capital Management 1.91M $31.08M March 31, 2014
T. Rowe Price Associates 1.75M $28.47M March 31, 2014
STATE STREET CORPORATION 1.55M $25.26M March 31, 2014
GOLDMAN SACHS 1.53M $24.91M March 31, 2014
Inves 1.48M $24.12M March 31, 2014
Paulson & Co 1.39M $22.63M March 31, 2014
SUSQUEHANNA INTERNATIONAL 1.35M $21.92M March 31, 2014
BlackRock Fund Advisors 1.34M $21.71M March 31, 2014
Consonance Capital 1.23M $19.94M March 31, 2014
BVF 1.14M $4.45M March 31, 2013
BlackRock Institutional Trust Company, N.A. 1.08M $17.55M March 31, 2014
Vanguard 1.00M $16.30M March 31, 2014
WALL STREET ASSOCIATES 705100 $11.46M March 31, 2014
BOGLE INVESTMENT MANAGEMENT L P /DE/ 606489 $9.86M March 31, 2014
A total of 22.41 million shares more ( DILUTION)
Average Purchase $ 331,910,000
Average total purchase: $14.81
Now you understand, why they want that you buy?
Besides dilution want to steal. Less
Now I understand analysts TDA
ResearchTeamTM Sell
TheStreet:Sell
S&P Capital IQ:No rating
Ford Equity Research: Strong Sell
MarketEdge:No rating
Jaywalk Consensus:Sell
Now one understands these ratings!
AMERICAN BULLS: MONDEY, CONFIRMATION: SELL!!
Signal Update
Our system’s recommendation today is to SELL. The BEARISH ONE BLACK CROW pattern finally received a confirmation because the prices crossed the confirmation level which was at 14,5800, and our valid average selling price stands now at 14,5000. The previous BUY recommendation was issued on 22/05/2014, 22 days ago, when the stock price was 9,9600. Since then VNDA has risen by +45,58%.
Market Outlook
We may be at a market top or at the start of a correction. The market ran out of steam and the traders are now more in agreement about the bearishness. The evidence is strong enough to prompt the closing of long positions. Today’s candlestick has a black body and its close is below the confirmation level. The bearish pattern that was previously identified is finally confirmed and a SELL signal is generated. You still have time to follow the signal and then you may start checking other securities for a bullish bet. Less
ZACKS:Ariad Pharmaceuticals had the Lowest Relative Performance in the Biotechnology Industry (ARIA, MNKD, BCRX, INSM, VNDA)
Jun 13, 2014 (Fast Lane via COMTEX) -- Below are five companies in the Biotechnology industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward.
Ariad Pharmaceuticals (NASDAQ:ARIA) ranks first with a loss of 8.69%; MannKind (NASDAQ:MNKD) ranks second with a loss of 5.51%; and BioCryst Pharmaceuticals (NASDAQ:BCRX) ranks third with a loss of 3.07%.
Insmed (NASDAQ:INSM) follows with a loss of 2.79% and Vanda Pharmaceuticals (NASDAQ:VNDA) rounds out the bottom five with a loss of 2.54%.ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers. Less
F.TIME:Markit short selling activity is High! 06/13/14
News of China and USA, Irak, are not encouraging.
I think we will have a black friday
Empire Asset Management initiates coverage at $6.00 at sell.
The chart is about to collapse + new coverage $6.00
Be carefull with the short sellers
Nice 8k for VNDA!
http://ih.advfn.com/p.php?pid=nmona&article=62514203&symbol=VNDA
Whooooo! Now that's how winners play! Well done!
Sold half call position for 80%....so far total on Strangle trade 115%
VNDA is rated BUY, based on 3 Wall Street analysts' reports. Analysts have an average $21.33 Target Price on VNDA, implying 78.8% Upside to its current price of $11.93.
Earnings 2/13 before bell
Time to start coming back down, approval already baked into the stock price. This has been good company to me in the past. :)
Not sure what news could come out to help stock higher, the drug they just had approved as a very small patient population it will service.
I'm holding a small portion of calls through March.
They will push this down as far as they can. I'm sure many bought above $13 and $14 and are now stuck holding the bag. But this would be a good entry point for when more news does pop like you say.
Wait and see....patience. The CC could mention something that would be good for another 10% pop. Tea leaves about pricing of product or any number of factors could drive this one either direction pretty quickly.
Be ready and nimble....the pop (if at all) would likely be short lived. Seems conformation bias plagues this one.
News already priced in it seems. I've seen this a few times where a stock drops on news as opposed to sky rocketing. I think it will pull back a bit more as people jump ship.
we had really good news now-now what, the shares are not responding according to the media buzz? how can that be?
Which is the exact reason I chose March options on this one. Let it shake out
Everyone looking to jump ship it seems....
Absolute battle right here at 14
VNDA...approved up big!
Yup....just exited my put side of my Strangle....run baby run
Then again.....odd price action
VNDA all over the place... Someone knows something
Nada....I keep scouring Twitter to see if it pops up. May be AH. We shall see
Well good luck to us both.
I've seen stocks that fall after FDA approval. But I don't think this will be one of them.
Yes , small amount.
sold @$13.04 now. better safe than sorry.
AH price=13.20 and thats just the beginning!
haven't decided yet. holding 1k @$13.30.
VNDA....who is holding through PDUFA? I bought 600 at 12.60 but Im liking the action the past two days.
Followers
|
34
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
397
|
Created
|
10/01/07
|
Type
|
Free
|
Moderators |
http://www.vandapharma.com/
http://www.vandapharma.com/development.html
http://finance.yahoo.com/q/ks?s=VNDA
Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients.
Our CEO, Mihael Polymeropoulos, MD, founded Vanda in 2003. Previously, he founded and ran the Novartis global Pharmacogenetics department, one of the industry leaders. Prior to that he worked for many years at the National Institute of Mental Health and the National Human Genome Research Institute, where he did pioneering work in gene mapping. He founded Vanda in partnership with Care Capital LLC, the prominent biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government with a focus on new biomedical enterprises.
Vanda has assembled an experienced team and a stable of clinical stage compounds to deliver on its vision.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads